The Role of Complement in Hereditary Angioedema
1University College London Hospitals NHS Foundation Trust, Department of Medicine, UK; Cardiometabolic Programme-NIHR UCLH/UCL BRC, London, UK; Amsterdam UMC, University of Amsterdam, Department of Vascular Medicine, Amsterdam, the Netherlands.
Insights
Hereditary angioedema (HAE) is caused by low C1 inhibitor levels, leading to attacks. New insights reveal bradykinin
Area of Science:
- Immunology
- Complement System
- Plasma Proteases
Background:
- Hereditary angioedema (HAE) is linked to low C1 inhibitor levels, causing debilitating attacks.
- C1 inhibitor regulates complement, coagulation, and fibrinolytic systems.
- Bradykinin overproduction, due to insufficient C1 inhibitor regulation, is key in HAE pathogenesis.
Purpose of the Study:
- To review recent findings on HAE pathophysiology.
- To discuss the role of bradykinin and C1 inhibitor in HAE.
- To highlight novel therapeutic strategies for HAE.
Main Methods:
- Review of recent scientific literature on hereditary angioedema.
- Analysis of the role of C1 inhibitor in complement, coagulation, and fibrinolysis.
- Examination of the kallikrein-kinin system in HAE pathogenesis.
Main Results:
- Low C1 inhibitor levels lead to angioedema attacks.
- Bradykinin plays a critical role in HAE pathophysiology.
- C1 inhibitor deficiency can activate coagulation and fibrinolytic pathways.
Conclusions:
- Understanding C1 inhibitor's role is crucial for HAE management.
- Bradykinin pathway modulation offers new therapeutic avenues for HAE.
- Novel treatments, including C1 inhibitor concentrates and bradykinin antagonists, are available for HAE.
Abstract:
Low levels of C1 inhibitor, the main inhibitor of the classic complement system, result in paroxysmal angioedema attacks that can be incapacitating or even life-threatening in affected individuals. Molecular defects in the gene for C1 inhibitor cause hereditary angioedema. In recent years, new insights in the pathways leading to angioedema due to a deficiency of C1 inhibitor have been gathered. Bradykinin, which is formed upon activation of the kallikrein-kinin system under insufficient regulation by C1 inhibitor, plays a crucial role. Whereas C1 inhibitor also occupies a central mediatory role in other plasma systems, such as the contact activation system of coagulation and the fibrinolytic plasminogen-plasmin system, a C1 inhibitor deficiency may also cause enhanced activation of these pathways. Novel therapeutic modalities for treatment and prevention of hereditary angioedema are now available, such as different forms of C1 inhibitor concentrate and novel agents that interfere in the kallikrein-kinin system.
Related Concept Videos
Complement System
Complementation Tests
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Allergic Reactions


